文献速递泌尿男性生殖肿瘤

卡博替尼在免疫检查点抑制剂治疗后转移性透明细胞肾细胞癌中的活性

Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
PubMed 文献 · Eur J Cancer · 2020-06-27

该回顾性多中心研究纳入86例经免疫检查点抑制剂(ICB)治疗后进展的转移性透明细胞肾细胞癌(ccRCC)患者,评估卡博替尼的疗效与安全性。结果显示客观缓解率(ORR)为36%,中位治疗失败时间(TTF)6.5个月,中位总生存(OS)13.1个月,12个月OS率55%,未观察到新的安全性信号。研究支持在ICB治疗后的患者中使用卡博替尼。

要点

  • 卡博替尼在ICB治疗后进展的ccRCC中ORR达36%,中位TTF 6.5个月。
  • 中位OS为13.1个月,12个月OS率55%。
  • 最常见导致减量的毒性为疲乏(27%)、手足综合征(16%)和腹泻(10%)。

核心结论

  • 卡博替尼在既往接受过ICB治疗的转移性ccRCC患者中具有活性,且未出现新的安全性信号,支持在ICB治疗后使用卡博替尼。

研究设计与样本

  • 回顾性分析来自2个学术中心的86例转移性ccRCC患者,这些患者在接受ICB单药、ICB联合VEGFi或ICB联合其他治疗后进展,随后接受卡博替尼治疗。

主要发现

  • 中位年龄63岁(范围33-84),中位既往治疗线数为2(范围1-10)。
  • 既往ICB类型:ICB单药64%,ICB联合VEGFi 29%,ICB联合其他治疗7%。
  • 卡博替尼治疗时,71%患者为IMDC良好或中危组;52%患者起始剂量为全剂量60 mg每日一次。
  • 客观缓解率(ORR)为36%(95%CI 26-47%),无完全缓解,43%达疾病稳定,21%原发性进展。
  • 中位治疗失败时间(TTF)为6.5个月(95%CI 5.3-8.5),中位总生存(OS)为13.1个月(95%CI 8.7-NR),12个月OS率为55%(95%CI 41-66%)。

关键数值与推荐

  • 常见导致减量的原因:疲乏27%,手足综合征16%,腹泻10%。

临床怎么用

  • 对于ICB治疗后进展的转移性ccRCC患者,卡博替尼是一种有效的后续治疗选择,需注意疲乏、手足综合征和腹泻等毒性并适时调整剂量。

局限性

  • 回顾性研究设计,样本量有限(86例),来自2个学术中心,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cabozantinib is approved for the first and subsequent line treatment of metastatic clear-cell renal cell carcinoma (ccRCC) based on trials in which most patients were immune checkpoint blockade (ICB) naive. With an expanding role of ICB in earlier lines of therapy, we assessed activity of cabozantinib in patients with metastatic ccRCC after progressing on anti-PD-1/PD-L1-based ICBs. METHODS: We retrospectively analysed the clinical outcomes of 86 patients from 2 academic centres who received cabozantinib after progression on ICB alone, ICB in combination with vascular endothelial growth factor inhibitors (VEGFis) or ICB in combination with other therapies. Overall response rate (ORR, investigator assessed), time to treatment failure (TTF), overall survival (OS) and toxicities leading to dose reductions or cessation were evaluated. RESULTS: Eighty-six patients were included in the analysis; the median age was 63 years (range 33-84) and the median number of prior therapies was 2 (range 1-10). The type of prior ICB therapy was ICBs alone (64%), an ICB in combination with a VEGFi (29%) or ICBs in combination with other therapies (7%). At the time of cabozantinib treatment, 71% of patients were in the International Metastatic RCC Database Consortium good- or intermediate-risk groups. Approximately half of patients (52%) were started on cabozantinib at the full 60 mg daily dose. The ORR was 36% (95% confidence interval [CI] = 26-47%) with no complete response and 43% achieving stable disease; 21% had primary progressive disease. The median TTF was 6.5 months (95% CI = 5.3-8.5.). The median OS was 13.1 months (95% CI = 8.7-NR) with 55% (95% CI = 41-66%) OS rate at 12 months. Most common reasons for dose reductions were fatigue (27%), palmar-plantar erythrodysesthesia (16%) and diarrhoea (10%). CONCLUSIONS: Cabozantinib is active in patients treated with prior ICB-based therapies, with no new safety signals. This study supports the use of cabozantinib after ICB-based therapies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. McGregor BA, Lalani AA, Xie W, et al. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2020. PMID: 32599410. doi:10.1016/j.ejca.2020.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。